LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply
AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.
-
Filed today
-
Companies tracked
NSE & BSE
Listed on
👋Welcome back, there - you're tracking 0 companies
🔔Sign in free to track companies and get alerts the moment they file
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors
Latest Filings -
📋 Filing Types Available on ForgeUp Filings
Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Procter & Gamble Health saw sales increase by 7% and profit by 45% for the quarter.
🤖 AI Summary
Sales for Procter & Gamble Health reached ₹356 crores for the quarter ended June 30, 2026, up 7% year-over-year.
Reported Profit After Tax (PAT) increased by 45% to ₹96 crores for the quarter ended June 30, 2026.
Operational PAT, excluding one-time asset sale proceeds, stood at ₹72 crores, representing a 9% increase year-over-year.
Growth attributed to strong brand fundamentals, superior retail execution, and positive consumer response to innovations.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Sales
₹356 crores
7%
Reported Profit After Tax (PAT)
₹96 crores
45%
Operational Profit After Tax (PAT)
₹72 crores
9%
🏢 How This Affects the Company
📈
Business Impact
The company's sales growth indicates continued demand for its VMS products and effectiveness of new innovations and retail execution strategies.
💰
Financial Impact
Reported PAT of ₹96 crores includes a boost from one-time asset sale proceeds, while operational PAT of ₹72 crores reflects core business profitability.
⚙️
Operational Impact
Strengthened supply chain and go-to-market capabilities supported the sales growth and improved operational profitability during the quarter.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results disclosure.
👤
Who Is Affected
All shareholders are affected as this filing provides an update on the company's financial performance for the first quarter of Financial Year 2026-2027.
🔍
Management Signal
Management is focused on driving balanced growth and value creation through a focused portfolio, superiority, and operational efficiency.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List - track these upcoming events
Q2 FY27 results — observe if sales growth above 7% is sustained.
Update on new innovations — assess impact on consumer response and market share.
Management commentary on future supply chain and go-to-market initiatives.
LOW RISKFiling reports positive financial results with no new risks identified.
💡 Investor Takeaway
Procter & Gamble Health reported sales of ₹356 crores, up 7% year-over-year, and reported PAT of ₹96 crores, up 45% for the quarter ended June 30, 2026. Operational PAT rose 9% to ₹72 crores, excluding one-time asset sale proceeds.
⚖️ Strengths & Concerns
✅ Positives
Sales increased by 7% to ₹356 crores for the quarter ended June 30, 2026, driven by strong brand fundamentals.
Reported Profit After Tax (PAT) grew by 45% to ₹96 crores, supported by sales growth and one-time asset sale proceeds.
⚠️ Concerns
A portion of the reported PAT growth for the quarter ended June 30, 2026, was due to one-time proceeds from an asset sale.
Operational PAT growth of 9% to ₹72 crores was lower than the reported PAT growth, indicating reliance on non-core income for overall PAT.
❓ Frequently Asked Questions
What were Procter & Gamble Health's sales for the quarter ended June 30, 2026?
Procter & Gamble Health reported sales of ₹356 crores for the quarter ended June 30, 2026, an increase of 7% from a year ago.
What was Procter & Gamble Health's reported Profit After Tax (PAT) for Q1 FY27?
The reported Profit After Tax (PAT) for Procter & Gamble Health for the quarter ended June 30, 2026, was ₹96 crores, up 45% year-over-year.
How much was Procter & Gamble Health's operational PAT for the quarter ended June 30, 2026?
Procter & Gamble Health's operational Profit After Tax (PAT) for the quarter ended June 30, 2026, was ₹72 crores, which is a 9% increase year-over-year, excluding one-time proceeds from an asset sale.
What contributed to Procter & Gamble Health's sales growth in Q1 FY27?
Sales growth was driven by strong brand fundamentals, superior retail execution, and positive consumer response to new innovations for the quarter ended June 30, 2026.
Questions based on this BSE filing only. For information purposes.
All BSE filings we have analysed for Procter & Gamble Health Ltd.
You've read one filing
There are 32,000 more, and one of them is about a company you own
Follow a company and we'll email you the moment it files
again - explained, not just forwarded. Free.
Follow companies and get filings by email
Save any filing to read later
Two full AI analyses every month, free
No card needed. Sign in with Google in two taps.
⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔖
Save filings you care about
Sign in free to save any filing and get notified when the same company files again.
🔖
Save This Filing
Sign in with Google to save this filing and get notified when this company files again. Free, takes 5 seconds.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.